All In Biotech

Drug Trial Radar · NCT00987441

Epidural Labor Analgesia and Infant Neurobehavior

Epidural Analgesia for Labor Pain and Infant Neurobehavior

Last checked: Nov 20, 2026Latest source record: Jul 27, 2011 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 1,200 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,200

Actual

Start

Sep 2009

Primary completion

Jul 2011

Study completion Jul 2011

Sponsor

Lead sponsor
Nanjing Medical UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Oct 1, 2009

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
Female only, from 19 years, up to 45 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Infant neurobehavior alteration is predictor of later intelligence development. Many factors would influence or are associated with infant neurobehavior, of which exist or appear during perinatal period. Neuraxial, especially epidural, analgesia to date is the most effective method in relieving labor pain. Although previous studies showed that opioid used in epidural analgesia for labor pain can affect newborn neurobehavior negatively in a dose-escalation associated manner, whether epidural analgesia itself would produce unpredictable effect on newborn neurobehavior is still unknown. Hereby the investigators designed this trial to investigate the hypothesis that epidural analgesia for labor pain control itself would not produce negative effect on infant neurobehavior.

Conditions

  • Labor Pain

Interventions

  • Ropivacaine and sufentanilDrug

    Ropivacaine 0.125% plus sufentanil 0.3 microgram

  • Ropivacaine and sufentanilDrug

    Ropivacaine 0.125% plus sufentanil 0.4 microgram

  • Ropivacaine and sufentanilDrug

    Ropivacaine 0.125% plus sufentanil 0.5 microgram

  • Ropivacaine and sufentanilDrug

    Ropivacaine 0.0625% plus sufentanil 0.4 microgram

  • Ropivacaine and sufentanilDrug

    Ropivacaine 0.1875% plus sufentanil 0.4 microgram

  • Ropivacaine and sufentanilDrug

    Ropivacaine 0.25% plus sufentanil 0.4 microgram

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Neurobehavior evaluation with the Assessment of Preterm Infants' Behavior (APIB)Time frame: Immediate after birth (0 min)

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • The Affiliated Nanjing Maternity and Child Health Care Hospital

    Nanjing, Jiangsu, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.